Abbott India Limited (ABBOTINDIA.NS)
INR 28755.5
(2.3%)
INR 28755.5
(2.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 16.97 Billion INR | 6.86% |
| 2022 | 13.56 Billion INR | 16.66% |
| 2021 | 11.61 Billion INR | 15.7% |
| 2020 | 9.98 Billion INR | 15.66% |
| 2019 | 8.7 Billion INR | 23.13% |
| 2018 | 7.15 Billion INR | 18.48% |
| 2017 | 6.37 Billion INR | 31.55% |
| 2016 | 4.52 Billion INR | 8.89% |
| 2015 | 4.12 Billion INR | 15.85% |
| 2014 | 3.59 Billion INR | 55.17% |
| 2013 | 2.55 Billion INR | 11.35% |
| 2012 | 2.34 Billion INR | 4.45% |
| 2011 | 1.95 Billion INR | 86.94% |
| 2010 | 1.05 Billion INR | -15.91% |
| 2009 | 1.26 Billion INR | 25.02% |
| 2008 | 995.8 Million INR | -3.81% |
| 2007 | 1.06 Billion INR | 14.69% |
| 2006 | 908.8 Million INR | 0.89% |
| 2005 | 898.2 Million INR | -36.06% |
| 2004 | 1.41 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.91 Billion INR | 11.61% |
| 2023 Q1 | 4.11 Billion INR | 24.64% |
| 2023 FY | - INR | 6.86% |
| 2023 Q4 | 3.29 Billion INR | -25.66% |
| 2023 Q3 | 4.43 Billion INR | 1.58% |
| 2023 Q2 | 4.36 Billion INR | 6.18% |
| 2022 FY | - INR | 16.66% |
| 2022 Q1 | 2.96 Billion INR | -5.75% |
| 2022 Q2 | 3.76 Billion INR | 26.98% |
| 2022 Q3 | 3.56 Billion INR | -5.41% |
| 2022 Q4 | 3.29 Billion INR | -7.48% |
| 2021 FY | - INR | 15.7% |
| 2021 Q4 | 3.14 Billion INR | 9.41% |
| 2021 Q3 | 2.87 Billion INR | 3.56% |
| 2021 Q2 | 2.77 Billion INR | -2.27% |
| 2021 Q1 | 2.84 Billion INR | 28.26% |
| 2020 FY | - INR | 15.66% |
| 2020 Q3 | 2.56 Billion INR | -2.26% |
| 2020 Q4 | 2.21 Billion INR | -13.67% |
| 2020 Q2 | 2.62 Billion INR | 0.66% |
| 2020 Q1 | 2.61 Billion INR | 56.73% |
| 2019 Q4 | 1.66 Billion INR | -37.72% |
| 2019 FY | - INR | 23.13% |
| 2019 Q1 | 2.03 Billion INR | 11.8% |
| 2019 Q2 | 2.33 Billion INR | 14.35% |
| 2019 Q3 | 2.67 Billion INR | 14.77% |
| 2018 FY | - INR | 18.48% |
| 2018 Q1 | 1.33 Billion INR | -19.43% |
| 2018 Q3 | 1.84 Billion INR | -15.75% |
| 2018 Q2 | 2.18 Billion INR | 64.18% |
| 2018 Q4 | 1.82 Billion INR | -1.01% |
| 2017 FY | - INR | 31.55% |
| 2017 Q2 | 2.16 Billion INR | 179.05% |
| 2017 Q4 | 1.65 Billion INR | -9.39% |
| 2017 Q3 | 1.82 Billion INR | -15.74% |
| 2017 Q1 | 775.5 Million INR | -0.98% |
| 2016 Q2 | 1.2 Billion INR | 0.84% |
| 2016 FY | - INR | 8.89% |
| 2016 Q3 | 1.36 Billion INR | 13.81% |
| 2016 Q1 | 1.19 Billion INR | 23.3% |
| 2016 Q4 | 783.2 Million INR | -42.82% |
| 2015 Q1 | 1.08 Billion INR | 32.9% |
| 2015 FY | - INR | 15.85% |
| 2015 Q3 | 1.14 Billion INR | 15.28% |
| 2015 Q4 | 967.9 Million INR | -15.48% |
| 2015 Q2 | 993.4 Million INR | -8.22% |
| 2014 Q3 | 984.5 Million INR | -1.77% |
| 2014 FY | - INR | 55.17% |
| 2014 Q2 | 1 Billion INR | 25.76% |
| 2014 Q1 | 796.9 Million INR | 31.77% |
| 2014 Q4 | 814.46 Million INR | -17.27% |
| 2013 Q2 | 724.4 Million INR | 47.27% |
| 2013 Q3 | 641.7 Million INR | -11.42% |
| 2013 Q4 | 604.78 Million INR | -5.75% |
| 2013 FY | - INR | 11.35% |
| 2013 Q1 | 491.9 Million INR | -5.91% |
| 2012 Q3 | 624.53 Million INR | 2.48% |
| 2012 Q1 | 501.8 Million INR | 214.21% |
| 2012 Q2 | 609.4 Million INR | 21.44% |
| 2012 Q4 | 522.8 Million INR | -16.29% |
| 2012 FY | - INR | 4.45% |
| 2011 Q3 | 648.24 Million INR | -5.34% |
| 2011 Q4 | 159.7 Million INR | -75.36% |
| 2011 Q2 | 684.8 Million INR | 0.0% |
| 2011 FY | - INR | 86.94% |
| 2010 FY | - INR | -15.91% |
| 2009 FY | - INR | 25.02% |
| 2008 FY | - INR | -3.81% |
| 2007 FY | - INR | 14.69% |
| 2006 FY | - INR | 0.89% |
| 2005 FY | - INR | -36.06% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cipla Limited | 67.19 Billion INR | 74.733% |
| Gland Pharma Limited | 13.33 Billion INR | -27.36% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | -91.345% |
| Kopran Limited | 744.13 Million INR | -2181.572% |
| Marksans Pharma Limited | 4.58 Billion INR | -270.232% |
| NGL Fine-Chem Limited | 678.68 Million INR | -2401.599% |
| Pfizer Limited | 8.23 Billion INR | -106.099% |
| Sanofi India Limited | 8.86 Billion INR | -91.452% |
| SMS Pharmaceuticals Limited | 1.21 Billion INR | -1302.222% |
| TTK Healthcare Limited | 999.34 Million INR | -1598.913% |